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Objective.—To investigate the association of migraine genetic variants with cerebral blood flow (CBF).
Background.—Migraine is a common disorder with many genetic and non-genetic factors affecting its occurrence. The exact 
pathophysiological mechanisms underlying the disease remain unclear, but are known to involve hemodynamic and vascular 
disruptions. Recent genome-wide association studies have identified 44 genetic variants in 38 genetic loci that affect the risk of 
migraine, which provide the opportunity to further disentangle these mechanisms.
Methods.—We included 4665 participants of the population-based Rotterdam Study (mean age 65.0  ±  10.9 years, 55.6% 
women). Cross-sectional area (mm2), flow velocity (mm/s), and blood flow (mL/min) were measured in both carotids and the 
basilar artery using 2-dimensional phase-contrast magnetic resonance imaging. We analyzed 43 previously identified migraine 
variants separately and calculated a genetic risk score (GRS). To assess the association with CBF, we used linear regression 
models adjusted for age, sex, and total brain volume. Hierarchical clustering was performed based on the associations with CBF 
measures and tissue enrichment.
Results.—The rs67338227 risk allele was associated with higher flow velocity and smaller cross-sectional area in the carotids 
(Pminimum  =  3.7  ×  10
−8). Other variants were related to CBF with opposite directions of effect, but not significantly after 
multiple testing adjustments (P  <  1.4  ×  10−4). The migraine GRS was not associated with CBF after multiple testing correc-
tions. Migraine risk variants were found to be enriched for flow in the basilar artery (λ  =  2.39).
Conclusions.—These findings show that genetic migraine risk is complexly associated with alterations in cerebral 
hemodynamics.
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INTRODUCTION
Migraine is a severe recurrent headache disorder 
affecting more than 800 million people worldwide.1 
Many genetic and non-genetic factors are known to 
be related to the risk of migraine, making it a com-
plex multifactorial disease. Non-genetic factors af-
fecting migraine risk include age and gender, as well 
as hormonal changes, diet, and stress among others. 
Genetic factors underlying its occurrence include 
44 genetic variants in 38 independent genetic loci, 
which have been identified in recent genome-wide 
association studies (GWAS).2 However, the biological 
pathways these genetic factors are acting upon remain 
poorly understood.
Most etiologic research on migraine revolves 
around 2 leading hypotheses, ie, the neuronal and the 
vascular hypothesis.3 Briefly, the neuronal hypothesis 
postulates that migraine is caused by neuronal events 
with changes in the cerebral blood flow (CBF) as a 
consequence, whereas the vascular hypothesis states 
that vascular and hemodynamic changes are the 
causal trigger of  migraine with subsequent activa-
tion of  perivascular nerves.4 Hemodynamic changes 
in the acute phase of  the disease include vasospasm 
and constriction, but in the interictal period between 
migraine attacks, the blood flow to the brain is in-
creased in patients with migraine compared to healthy 
individuals.5
Recently, genetic loci underlying migraine have 
shown to be enriched for both vascular and neuro-
nal pathways.2 Now, more and more ground has been 
gained by the “neurovascular hypothesis,” assuming an 
interplay of both vascular and neuronal factors to be 
involved in the development of migraine.6,7 Yet, while 
many genetic loci have been replicated to associate with 
migraine, it remains unclear how these affect cerebral 
hemodynamics.
Therefore, in this study, we further investigated the 
relationship between genetic variation associated with 
migraine and cerebral vascular changes, which may 
underlie the pathophysiology of migraine.
MATERIAL AND METHODS
Study Population.—This study was conducted 
within the Rotterdam Study, an ongoing population-
based cohort study which aims to investigate the 
causes and determinants of diseases affecting elderly 
people.8 This longitudinal cohort study was initiated in 
1990 and extended in 2000 and 2006, with a total of 
14,926 participants aged 45 years and over. At baseline, 
blood samples were drawn to perform genotyping 
(N  =  11,496). In 2005, magnetic resonance imaging 
(MRI) was added to the study protocol, and all individu-
als were invited to undergo MRI scanning from that 
time onward. Since this scanning protocol was 
implemented 15 years after the initiation of the Rotter-
dam Study in 1990, brain imaging was only available in 
a subset of 4865 individuals with genotyping data. The 
Rotterdam Study has been approved by the Medical 
Ethics Committee of the Erasmus MC (registration 
number MEC 02.1015) and the Ministry of Health, 
Welfare and Sports of the Netherlands (Population 
Screening Act WBO, license number 1071272-159521-
PG). All participants have given written informed 
consent.8
We included 4865 participants for whom both 
genotyping and phase-contrast brain MRI was per-
formed between 2005 and 2015. Of those, participants 
with cortical brain infarcts (N  =  200) were excluded 
from the analyses, since this can interfere with imaging 
processing which can consequently limit the reliability 
of MRI-derived metrics.
Genotyping.—At baseline, genotyping was performed 
in 11,496 individuals of the Rotterdam Study using 
Illumina 550K, 550K duo, or 610 quad arrays. 
The generation and management of genotype data 
for the Rotterdam Study were executed by the Human 
Genotyping Facility of the Genetic Laboratory 
of the Department of Internal Medicine, Erasmus 
MC, Rotterdam, the Netherlands. Samples with a 
call rate below 97.5%, as well as gender mismatches, 
excess autosomal heterozygosity, duplicates or family 
relations, ethnic outliers, variants with call rates lower 
than 95.0%, failing missingness test, Hardy-Weinberg 
equilibrium P  <  10−6, and allele frequencies below 
1%, were removed. Genotypes were imputed using the 
MaCH/minimac software to the 1000 Genomes phase 
I version 3 reference panel.9
*These authors contributed equally to this work.
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Genetic Risk Scores.—We calculated a weighted 
genetic risk score (GRS) using the summary statistic 
data of the most recent migraine GWAS meta-analysis.2 
We included all independent genome-wide significant 
autosomal variants (N = 43) and excluded rs12845494 
located on chromosome X, since imputations of 
X chromosome variants were not available. For these 
genetic variants, we multiplied the reported effect 
estimate by the allele dosage for every participant. 
These weighted effects were then added up to create 
a GRS, which was subsequently standardized into a 
Z-score.
Measurement of CBF.—The brain MRI proce-
dure has been described in more detail elsewhere.10 In 
short, 2-dimensional phase-contrast imaging was per-
formed on a dedicated 1.5 tesla MRI scanner. In the 
basilar artery and in the left and right carotid arter-
ies, the vessel’s cross-sectional area (mm2) measured, as 
well as flow velocity (mm/s) and blood flow (mL/min), 
were measured.11 These values were standardized to 
facilitate comparisons across individuals. Values more 
than 3.5 standard deviations from the mean were con-
sidered outliers and excluded from the analyses. Total 
CBF was calculated by adding up the blood flow esti-
mates of the 3 arteries (mL/min). Total brain volume 
was computed as the sum of gray matter, white mat-
ter, and white matter lesion volumes, as obtained by the 
k-nearest neighbor classifier.12
Migraine Assessment.—Migraine assessment was 
done either by home or phone interview. We used a 
questionnaire based on the International Classifica-
tion of Headache Disorders – 2nd edition (ICHD-II) 
migraine headache criteria,13 slightly modified 
from the validated questionnaire of the Genetic Epi-
demiology of Migraine Study.14 Migraine was defined 
as a lifetime occurrence of more than 5 headache 
attacks with a duration of 4-72 hours when untreated, 
accompanied with typical characteristics of migraine 
headaches and photophobia or nausea. Migraine was 
classified as the active migraine subtype if  the last mi-
graine attack occurred less than 1 year ago. The prob-
able migraine subtype was defined as having 2 or more 
attacks and all other above-mentioned criteria, or per-
sons with 5 attacks with a duration of 4-72 hours and 
all but one of the other criteria.
Data Analysis.—As a validation of the migraine 
GWAS results, we performed logistic regression anal-
yses adjusted for age and sex to estimate the associ-
ation of the migraine GRS with migraine, as well as 
migraine subtypes. Linear regression models were 
used to assess the association of the GRS and genet-
ic variants separately with CBF parameters, adjusted 
for age, sex, and total brain volume. Since CBF mea-
sures within and between blood vessels in the brain 
can be correlated, we performed permutation testing 
(N  =  10,000) to define the number of independent 
CBF measures. Hereto, we rerun the above-men-
tioned linear regression models for the different CBF 
parameters, and replaced the genetic variables with 
a random variable, which we repeated 10,000 times. 
Each time, the minimum P value of all regressions 
for the different outcomes was saved. These P val-
ues were sorted, and the P value threshold divid-
ing the 5% lowest and the 95% highest P values was 
defined. Subsequently, we divided .05 by this threshold 
in order to calculate the number of independent tests. 
This showed that, out of  the 10 measures for CBF 
(cross-sectional area, flow velocity and blood flow 
in 3 arteries, and total CBF), 8.2 were independent. 
This number was used to correct for multiple testing, 
resulting in a P value threshold of 6.1 × 10−3 (.05/8.2) 
for the GRS analyses. In the single-variant analyses, we 
additionally adjusted for the number of genetic vari-
ants tested, which resulted in a P value threshold of 
1.4  ×  10−4 (.05/[43  ×  8.2]), because these 43 genetic 
variants were previously shown to be located in in-
dependent loci. Since individual genetic variants may 
be in the same pathway, and thus act in concordance 
with each other, we grouped the 43 genome-wide sig-
nificant autosomal variants using hierarchical cluster-
ing. In a first approach, clusters were created based 
on their association with vessel area, velocity, and 
flow in the basilar and carotid arteries, in order to 
create groups of genetic variants with similar effects 
on CBF. In a second approach, we created groups by 
clustering the genetic variants according to similarities 
in their associated genes’ P value for tissue enrichment 
in brain, vascular, and gastrointestinal tissues from 
the GTEx collection, as previously reported.2  
We created a tanglegram to visualize the overlap be-
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tween the clusters created by the 2 different hierarchical 
clustering approaches, enabling us to explore whether 
genetic variants with similar tissue enrichments also 
had similar associations with CBF parameters. Addi-
tionally, we created GRS of the genetic variants in the 
different tissue clusters and studied the combined 
effect of  the variants by relating these GRS to CBF 
measures. Still, effects on CBF within tissue clusters 
may be heterogeneous. Therefore, we also studied the 
enrichment of the genetic variants’ associations for 
CBF in the different tissue clusters by comparing their 
genomic inflation factor λ for the different CBF mea-
sures, and calculated confidence intervals around the 
null, ie, λ  =  1, using 10,000 permutations. R version 
3.2.5 was used to create GRS, and to perform logis-
tic and linear regression analyses, hierarchical cluster-
ing, and permutation testing. The R package “dendex-
tend” was used to perform hierarchical clustering.
RESULTS
We included 4665 participants of the Rotterdam 
Study with an average age of 65.0  ±  10.9 years, of 
which 55.6% were women, and of which 16.7% were 
classified as having migraine. A complete overview of 
the descriptive statistics is presented in Table 1.
Validation GRS Migraine.—The GRS for migraine 
was associated with an increased risk of  migraine 
(adjusted odds ratio [OR] 1.30, 95% confidence in-
terval [CI] 1.19-1.41) and the different migraine sub-
types (Fig. 1). Also, a quantile-quantile plot of  the 
43 migraine risk variants showed enrichment for 
migraine (λ = 2.39) (Fig. 2). Since there was a small 
overlap of  individuals who were included in the 
Table 1.—Descriptive Statistics
Variable N = 4665
Age (years), mean ± SD 65.0 ± 10.9
Female, N (%) 2592 (55.6)
Migraine, N (%) 703 (16.7)
Migraine with aura 145 (4.0)
Active migraine 282 (7.4)
Probable migraine 177 (4.8)
Total CBF (mL/min), mean ± SD 521.6 ± 101.1
Basilar artery
Area (mm2), mean ± SD 28.7 ± 5.0
Flow (mL/min), mean ± SD 1.7 ± 0.6
Velocity (mm/s), mean ± SD 11.1 ± 4.4
Left carotid artery
Area (mm2), mean ± SD 35.4 ± 6.7
Flow (mL/min), mean ± SD 3.5 ± 0.9
Velocity (mm/s), mean ± SD 15.1 ± 4.6
Right carotid artery
Area (mm2), mean ± SD 36.3 ± 7.0
Flow (mL/min), mean ± SD 3.5 ± 0.9
Velocity (mm/s), mean ± SD 14.8 ± 4.5
N = number of participants; SD = standard deviation.
Fig. 1.—Associations between the migraine GRS and migraine diagnoses. Forest plot showing association results between the migraine 
GRS and different migraine subtypes. Confidence interval (CI); sample size (N);  number of cases (n); odds ratio (OR); standard 
deviation (SD).
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original migraine GWAS (0.6% of  the total GWAS 
sample), we also removed this subset to verify 
that there was no overfitting and found similar effect 
estimates (Supporting Table S1).
Migraine Genetic Variants and CBF.—The migraine 
GRS was associated with blood flow in the basilar 
artery (β = 0.03, P = .040), although this did not survive 
correction for multiple testing (P < 6.1 × 10−3) (Fig. 3). 
One genetic variant, rs67338227, was significantly re-
lated to smaller vessel area and higher velocity in both 
carotid arteries (minimal P = 3.7 × 10−8), but no relation 
was found with blood flow in any of the arteries. 
Interestingly, other genetic variants showed associa-
tions with CBF measures in the opposite direction of 
effect compared to rs67338227 (minimal P = 2.6 × 10−4) 
(Supporting Table S2). These associations survived 
adjustments for the number of independent outcomes 
under investigation, but were not significant after adjust-
ing for both the number of independent outcomes and 
the number of genetic variants tested (P < 1.4 × 10−4).
Hierarchical Cluster Analysis.—Because the genetic 
variants’ risk alleles showed heterogeneous associa-
tions with CBF, we hierarchically clustered the variants 
according to their estimated effect on measures of CBF 
(Supporting Fig. S1 and Supporting Table S3). Two 
out of the 4 created clusters mainly included variants 
associated with CBF; 1 cluster mainly contained genetic 
Fig. 2.—Quantile-quantile plot of the migraine genetic variants 
and prevalence of migraine.
Fig. 3.—Associations between genetic risk variants for migraine and CBF. Plot showing association results between the migraine 
GRS and the 3 top genetic variants. Colors and sizes of the blocks correspond to t values, with blue and red indicating positive and 
negative associations, respectively. Larger blocks indicate stronger associations, and significance levels are noted by asterisks: * for 
P value <.05, ** for P value <.05/8.2 = 6.1 × 10−3, and *** for P value <.05/(43 × 8.2) = 1.4 × 10−4.
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variants linked to larger vessel areas and lower veloci-
ties, whereas the other cluster primarily contained vari-
ants related to smaller vessel areas and higher velocities. 
We additionally clustered the genetic variants accord-
ing to the tissue enrichment in brain, vascular, and 
gastrointestinal tissues of their associated genes, which 
was available for 39 genetic variants (Supporting Table 
S4 and Fig. 4). Four clusters were created, containing 
genetic variants linked to genes with enrichment in the 
following tissues: enrichment in all 3 tissues (brain, 
vascular, and gastrointestinal; N  =  9); enrichment in 
brain tissue (N  =  5); enrichment in vascular tissue 
Fig. 4.—Associations between genetic risk variants for migraine and CBF, hierarchically clustered based on the enrichment 
of their associated genes in brain, vascular, and gastrointestinal tissues. Plot showing association results between 39 autosomal 
migraine genetic risk variants and measures of CBF, including a dendrogram based on the tissue enrichment in brain, vascular, and 
gastrointestinal tissues of their associated genes. The genetic variants in each cluster are linked to genes that are differentially enriched 
in tissues: vascular, brain, and gastrointestinal tissues (purple branches); brain tissue (green branches); vascular and gastrointestinal 
tissues (yellow branches); vascular tissue (pink branches). Colors and sizes of the blocks correspond to t values, with blue and red 
indicating positive and negative associations, respectively. Significance levels are noted by asterisks: * for P value <.05, ** for P value 
<.05/8.2 = 6.1 × 10−3, and *** for P value <.05/(43 × 8.2) = 1.4 × 10−4.
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(N = 13); enrichment in vascular and gastrointestinal 
tissues (N = 12). As shown in Supporting Table S5 and 
Supporting Fig. S2, the grouping based on CBF and 
tissue enrichment clustering were not strongly correlated. 
However, the cluster with enrichment in vascular tis-
sue only (N = 13) included all 3 top genetic variants 
presented in Figure 3. GRS combining the associa-
tions of the genetic variants in these clusters did not 
relate to CBF measures significantly (Fig. 5). Nonethe-
less, we did observe enrichment of the migraine risk 
variants for flow in the basilar artery (λ = 2.39) (Fig. 6, 
Supporting Table S6 and Supporting Fig. S3), which 
Fig. 5.—Associations between 4 migraine GRS, containing genetic variants based on tissue enrichment patterns, and CBF. Plot 
showing association results between migraine GRS and measures of CBF. Clusters of 39 genome-wide significant genetic variants 
for migraine were created based on the tissue enrichment in brain, vascular, and gastrointestinal tissues of their associated genes, 
as presented in Figure 4. Weighted GRS of the genetic variants in each cluster were calculated to estimate the combined effect 
of the variants in each cluster. Colors and sizes of the blocks correspond to t values, with blue and red indicating positive and 
negative associations, respectively. Larger blocks indicate stronger associations, and significance levels are noted by asterisks: 
* for P value <.05, ** for P value <.05/8.2 = 6.1 × 10−3. Genetic risk score (GRS).
Fig. 6.—Enrichment of the migraine genetic variants for measures of CBF, overall and stratified by tissue enrichment cluster. 
Plot showing enrichment results of migraine genetic risk variants for measures of CBF. The overall λ for all 43 genetic variants 
is represented, as well as for clusters of variants linked to genes that are differentially enriched in tissues: vascular, brain, and 
gastrointestinal tissues (cluster 1, purple bars, N = 9); brain tissue (cluster 2, green bars, N = 5); vascular and gastrointestinal tissues 
(cluster 3, yellow bars, N = 12); vascular tissue (cluster 4, red bars, N = 13), as shown in Figure 4. Confidence intervals around the 
null, ie, λ = 1 (long-dashed gray lines), are shown in gray dashed lines.
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was equal to the enrichment observed for migraine. 
The enrichment was even stronger in the first cluster, 
containing variants nearby genes expressed in brain, 
gastrointestinal, and vascular tissues (λ  =  3.53), and 
in the fourth cluster, containing variants nearby genes 
expressed in vascular tissue (λ = 3.36).
DISCUSSION
In this study, we found that the known migraine 
variant rs67338227 was significantly associated with 
CBF measures after adjustments for multiple testing 
(P < 1.4 × 10−4). Other genetic variants identified for 
migraine showed associations in opposite directions 
of effect although they did not survive multiple test-
ing correction. Significant enrichment was observed 
for the migraine variants’ associations with flow in the 
basilar artery.
We found that genetic variants associated with mi-
graine also showed associations with CBF. This finding 
builds upon a previously performed gene enrichment 
analysis, which showed enrichment of migraine vari-
ants for genes expressed in vascular and smooth muscle 
tissue.2 Also, migraine has been shown to genetically 
overlap with other vascular phenotypes, such as coro-
nary artery disease and ischemic stroke.15,16 Moreover, 
in a GWAS for CBF performed in the Rotterdam 
Study, the 2 genome-wide significant variants were 
located in loci that had earlier been associated with 
migraine,17 which already suggested a genetic overlap 
between migraine and CBF. This study thus adds to 
the evidence supportive of structural hemodynamic 
changes involved in migraine.
Interestingly, significant associations were ob-
served between individual migraine variants and CBF, 
but not for the migraine GRS including all autosomal 
genome-wide significant variants for migraine. Usually, 
a GRS is considered a measure of the combined effect 
of multiple genetic variants. An underlying assump-
tion is thus that the genetic variants’ magnitude and 
direction of effect for the association with the outcome 
of interest is similar or equal to the effect estimate used 
to create the GRS. In our study, the individual vari-
ants indeed showed associations in the same direction 
in relation to migraine, but varying effect estimates in 
opposite directions were observed when the variants 
were related to measures of CBF. This characterizes 
the complex relation between migraine and CBF, 
and is in line with previous studies that showed both 
hypo- and hyperperfusion in migraine patients.18,19 The 
varying associations with CBF might be attributed to 
a distorted autoregulation in people with migraine, 
resulting in higher fluctuations in CBF, as previous 
studies already suggested.20,21 More research is needed 
to further explore possible pathways through which 
the identified migraine variants may affect CBF. A 
formal mediation analysis could be performed in fu-
ture research to examine whether the migraine genetic 
variants are affecting disease risk through CBF alter-
ations. Moreover, genetic variants that did not reach 
genome-wide significance for migraine could be taken 
into account, since this would increase the explained 
variance for migraine, and may therefore give a more 
complete picture of their association with CBF as well. 
Although clusters of genetic variants linked to genes 
with enrichment in vascular tissues contained the ge-
netic variants with the strongest CBF associations, the 
combined effect estimates of the different clusters on 
CBF remained marginal. Therefore, alternative meth-
ods to separate clusters of genetic variants based on 
their pathophysiology could be considered, which 
in turn may help elucidating the different biological 
pathways leading to migraine. Furthermore, lead ge-
netic variants identified in a GWAS are not necessar-
ily the causal variant associated with disease. Hence, 
studies investigating which variants or genes are most 
likely causal would be valuable to gain more insight 
into the role of cerebral hemodynamics in migraine 
pathophysiology.
Findings of  this study suggest that total CBF 
may not be a comprehensive measure when study-
ing vascular changes involved in migraine. Although 
many nominal significant associations were shown 
between migraine risk variants and CBF measures, 
no nominal significant associations were found for 
total CBF. We showed that migraine variants asso-
ciated with the vessel’s area and its blood velocity 
with opposite directions of  effects, resulting in a null 
effect on its blood flow since flow is a cross prod-
uct of  area and velocity. This observation is in line 
with findings of  the CBF GWAS, in which one of 
the hits (rs2971609) was associated with vessel area 
and flow velocity, but had a null effect on the vessels’ 
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flow rate.17 Additionally, the migraine variants’ asso-
ciations were often not similar across blood vessels, 
consistent with previous studies that showed loca-
tion-specific or asymmetric changes in CBF mea-
sures.22-24 Consequently, blood flow might not seem 
to be affected when not all CBF measures are exam-
ined together, whereas there are in fact hemodynamic 
changes present in the brain.
Pathways associated with migraine include both 
neuronal and vascular components,25 suggesting a 
shared vascular and neuronal component underlying 
the development of  migraine. In our study, the genetic 
variant rs67338227, located in the 4 and a half  LIM 
domains 5 and UFM1-specific ligase (FHL5/UFL1) 
locus, showed a significant association with measures 
of  CBF. UFL1 produces a protein located in the en-
doplasmic reticulum membrane, and is involved in 
hematopoietic stem cell function and hematopoiesis 
in mice,26,27 as well as signaling pathways including 
NF-κB signaling and protein ufmylation.28 FHL5 
produces a protein that interacts with the transcrip-
tion factor cAMP-responsive element modulator.29 
Although this gene has mainly been described in the 
context of  spermatid differentiation into mature sper-
matozoa, it is also highly expressed in vascular tissue.30 
Altogether, FHL5/UFL1 is a plausible locus involved 
in the link between migraine and CBF as it is involved 
in both neuronal and vascular pathways. Functional 
studies are needed to further look into mechanisms 
through which these genes could affect both migraine 
and CBF, and whether intervening in these pathways 
could influence migraine symptoms or occurrence.
Strengths of this study are the large sample size 
and the population-based setting, which allowed us 
to include a broad spectrum of people with and with-
out migraine, ie, also including those suffering from 
migraine not diagnosed by a medical specialist. There 
are also limitations we need to take into consideration. 
First, we only assessed CBF during the interictal pe-
riod of participants with migraine, which did not allow 
us to look at the effect of the genetic variants on CBF 
during a migraine attack. Second, we only measured 
CBF in 3 large brain vessels, whereas vascular changes 
in smaller brain vessels may be more critical in patho-
physiological mechanisms underlying migraine. Yet, 
this has most likely led to an underestimation of the ef-
fect estimates found. Finally, a part of the study popu-
lation (N = 2392) was included in the discovery GWAS 
for migraine. However, this only accounts for 0.6% of 
the total study population in the meta-analysis,2 and 
in a sensitivity analysis excluding overlapping partici-
pants, we did not observe substantial differences of the 
associations.
In conclusion, in this study, we found enrichment 
of migraine genetic variants for measures of CBF. 
These findings are supportive of an involvement of 
structural cerebral hemodynamic changes in migraine 
pathophysiology. Future studies are needed to further 
elucidate pathways through which CBF is influenced 
by migraine variants.
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